PharmaLundensis (PHAL) Q2 2025 earnings summary

Executive summary

• Net sales remained at 0 SEK for both the six-month and three-month periods compared to the same periods last year.

• Net loss after financial items increased to -3,521,132 SEK for six months and -2,074,093 SEK for three months, both worsening year-over-year.

• Equity ratio as of June 30, 2025, was 37%.

• Recent share issue raised approximately 3.13 million SEK, providing operational funding into next year.

• Focus remains on demonstrating and selling the new Förevaporeringsenheten and optimizing the Phal-501 synthesis for clinical trials.

Financial highlights

• Net loss after financial items for six months: -3,521,132 SEK (vs. -1,522,939 SEK year-over-year).

• Net loss after financial items for three months: -2,074,093 SEK (vs. -351,221 SEK year-over-year).

• Earnings per share for six months: -0.07 SEK (vs. -0.04 SEK year-over-year).

• Earnings per share for three months: -0.04 SEK (vs. -0.01 SEK year-over-year).

• No dividend for 2024; all profits retained.

Outlook and guidance

• Capital from the summer share issue is expected to fund operations into next year, but not cover all outstanding debt.

• Demonstrations of the Förevaporeringsenheten are planned for autumn, with potential sales to improve financial position.

• Ongoing evaluation of new funding options for the pharmaceutical project, including partnerships or spin-offs.